The treatment using a MEK inhibitor binimetinib, both in vitro and in vivo, inhibited the corticotroph tumor cell proliferation, POMC transcription, and ACTH secretion, rendering it a possible candidate for Cushing’s disease treatment [125]. Here, POMC is linked to neoplasm.